Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for RZLT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
March 31, 2026 -13.74M
December 31, 2025 -20.32M
September 30, 2025 -17.43M
June 30, 2025 -22.00M
March 31, 2025 -17.40M
December 31, 2024 -13.67M
September 30, 2024 -16.01M
June 30, 2024 -18.52M
March 31, 2024 -15.24M
December 31, 2023 -13.02M
September 30, 2023 -10.58M
June 30, 2023 -11.35M
March 31, 2023 -18.05M
December 31, 2022 -7.493M
September 30, 2022 -7.589M
June 30, 2022 -12.11M
March 31, 2022 -13.97M
December 31, 2021 -7.197M
September 30, 2021 -6.341M
June 30, 2021 -5.155M
March 31, 2021 -5.472M
December 31, 2020 -6.263M
September 30, 2020 -3.551M
June 30, 2020 -4.078M
March 31, 2020 -5.679M
Date Value
December 31, 2019 -5.482M
September 30, 2019 -8.929M
June 30, 2019 -3.764M
March 31, 2019 -8.457M
December 31, 2018 -1.651M
September 30, 2018 -1.432M
June 30, 2018 -3.883M
March 31, 2018 -2.178M
December 31, 2017 -3.148M
September 30, 2017 -4.905M
June 30, 2017 -3.644M
March 31, 2017 -3.609M
December 31, 2016 -3.091M
September 30, 2016 -2.968M
June 30, 2016 -3.152M
March 31, 2016 -2.538M
December 31, 2015 -2.285M
September 30, 2015 -2.514M
June 30, 2015 -1.963M
March 31, 2015 -1.908M
December 31, 2014 -1.740M
September 30, 2014 -1.469M
June 30, 2014 -2.098M
March 31, 2014 -0.7076M
December 31, 2013 -0.3653M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
SELLAS Life Sciences Group, Inc. -7.588M
AbbVie, Inc. 3.436B
Marker Therapeutics, Inc. -3.716M
Avalo Therapeutics, Inc. -19.99M
Krystal Biotech, Inc. 74.79M